CIK Treatment Extends Progression-free Survival of Glioblastoma Patients by 1.5 Times
Fresh News,
. The ‘Immuncell-LC’-treated group demonstrated to be 30% higher in DCR without serious additional adverse effects.
. The ‘Immuncell-LC’-treated group demonstrated to be 30% higher in DCR without serious additional adverse effects.
] The paper entitled " Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed…
SEOUL, South Korea--(BUSINESS WIRE)-- The paper entitled “” was recently published in online edition of the ‘Oncotarget’, an…
SEOUL, South Korea--(BUSINESS WIRE)-- The paper entitled " Phase III randomized trial of autologous cytokine-induced killer…
SEOUL, South Korea--(Business Wire)--The paper entitled “ Phase III randomized trial of autologous cytokine-induced killer cell…
SEOUL, South Korea--( BUSINESS WIRE )--The paper entitled “ Phase III randomized trial of autologous cytokine-induced killer…
SEOUL, South Korea--(BUSINESSWIRE)-- The paper entitled “ Phase III randomized trial of autologous cytokine-induced killer cell…
The paper entitled “” was recently published in online edition of the ‘Oncotarget’, an international journal of authority in…
SEOUL, South Korea--(BUSINESS WIRE)-- The paper entitled “ Phase III randomized trial of autologous cytokine-induced killer…
CIK Treatment Extends Progression-free Survival of Glioblastoma Patients by 1.5 Times.
Oct. 5, 2016 11:00 UTC SEOUL, South Korea--( BUSINESS WIRE )-- The paper entitled “ Phase III randomized trial of autologous…
SEOUL, South Korea--( BUSINESS WIRE )--The paper entitled “ Phase III randomized trial of autologous cytokine-induced killer…